We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Cullinan Management Inc (CGEM) USD0.0001

Sell:$16.17 Buy:$16.21 Change: $0.98 (5.70%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.98 (5.70%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.98 (5.70%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cullinan Oncology, Inc., formerly Cullinan Management, Inc. is a biopharmaceutical company. The Company is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.

Contact details

One Main Street, Suite 520
United States
+1 (617) 4104650

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$723.42 million
Shares in issue:
43.68 million
United States
US dollar

Key personnel

  • Nadim Ahmed
    President, Chief Executive Officer, Director
  • Patrick Baeuerle
    Co-Founder, Acting Chief Scientific Officer - Biologics
  • Jeff Trigilio
    Chief Financial Officer, Treasurer
  • Raymond Keane
    Chief Legal Officer
  • Jennifer Michaelson
    Chief Development Officer - Biologics
  • Corinne Savill
    Acting Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.